Åpne denne publikasjonen i ny fane eller vindu >>Vise andre…
2023 (engelsk)Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 201, nr 2, s. 234-248Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
The human homologues of murine double minute 2 (MDM2) and 4 (MDM4) negatively regulate p53 tumour suppressor activity and are reported to be frequently overexpressed in human malignancies, prompting clinical trials with drugs that prevent interactions between MDM2/MDM4 and p53. Bone marrow samples from 111 patients with acute myeloblastic leukaemia, myelodysplastic syndrome or chronic myelomonocytic leukaemia were examined for protein (fluorescence-activated cell sorting) and messenger RNA (mRNA) expression (quantitative polymerase chain reaction) of MDM2, MDM4 and tumour protein p53 (TP53). Low protein expression of MDM2 and MDM4 was observed in immature cells from patients with excess of marrow blasts (>5%) compared with CD34+/CD45low cells from healthy donors and patients without excess of marrow blasts (<5%). The mRNA levels were indistinguishable in all samples examined regardless of disease status or blast levels. Low MDM2 and MDM4 protein expression were correlated with poor survival. These data show a poor correlation between mRNA and protein expression levels, suggesting that quantitative flow cytometry analysis of protein expression levels should be used to predict and validate the efficacy of MDM2 and MDM4 inhibitors. These findings show that advanced disease is associated with reduced MDM2 and MDM4 protein expression and indicate that the utility of MDM2 and MDM4 inhibitors may have to be reconsidered in the treatment of advanced myeloid malignancies.
sted, utgiver, år, opplag, sider
John Wiley & Sons, 2023
Emneord
acute myeloid leukaemia, murine double minute 2 (MDM2), murine double minute 4 (MDM4), myelodysplastic syndrome, p53
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-202253 (URN)10.1111/bjh.18608 (DOI)000901620500001 ()36546586 (PubMedID)2-s2.0-85145072715 (Scopus ID)
Forskningsfinansiär
European Regional Development Fund (ERDF), CZ.02.1.01/0.0/0.0/16_019/0000868Swedish Cancer SocietyCancerforskningsfonden i Norrland, 160598Swedish Research Council
2023-01-052023-01-052023-07-14bibliografisk kontrollert